Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00999752 · ClinicalTrials.gov registry record · NA
Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension
A NA study, sponsored by InVasc Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00999752 is a NA study that has completed, run by InVasc Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT00999752, a NA study, has completed, sponsored by InVasc Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.
Interventions
- DRUG Nebivolol
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00999752
The ClinicalTrials.gov registry entry for NCT00999752 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InVasc Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nebivolol is the first listed.
NCT00999752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00999752 about?
NCT00999752 is a clinical study titled "Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension". The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.
What is the current status of trial NCT00999752?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2009-10. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00999752?
The interventions under investigation include: Nebivolol (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00999752?
This trial is sponsored by InVasc Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.